The FDA has approved three self-administered tests for the high-risk strains of HPV known to cause most cervical cancers.
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback